About Rakovina

Building the next generation of cancer therapies.

Rakovina Therapeutics is a biopharmaceutical research company focused on the development of innovative cancer treatments. Our work is based on unique technologies for targeting the DNA-damage response powered by Artificial Intelligence (AI). By using AI, we can review and optimize drug candidates at a much greater pace than ever before.

The Company has established a pipeline of distinctive DNA-damage response inhibitors with the goal of advancing one or more drug candidates into human clinical trials in collaboration with pharmaceutical partners.

Leadership

Kim Oishi, MBA

Chief Executive Officer

Mads Daugaard, PhD

President & Chief Scientific Officer

David Kideckel, PhD, MBA

Chief Financial Officer

John Langlands, PhD

Head of Development

Michelle Seltenrich, MBA

Vice President, Operations

Mark Mitchell, MSc

Director, Strategy & Capital Markets

Board of Directors

Kim Oishi, MBA

Frank Holler, MBA & BA Econ

Yevgeniy Meshcherekov, CPA

David Kideckel, PhD

Petra Hamerlik, PhD

Scientific Advisory Board

Dennis Brown, PhD, BA, MS

SAB Chair

Artem Cherkasov, PhD

SAB Member

Petra Hamerlik, PhD

SAB Member

Leonard Post, PhD, BS

SAB Member

Ranjit Bindra, PhD

SAB Member